|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-6-14
|
|
pubmed:abstractText |
Uracil-tegafur (UFT) has been reported to have a broad anti-tumor activity in a variety of malignancies including colorectal cancer and breast cancer. However, its activity in pancreatic cancer has not been fully evaluated. The aim of the present study was to evaluate the anti-tumor activity and toxicity of UFT in patients with metastatic pancreatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
223-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12065869-Adenocarcinoma,
pubmed-meshheading:12065869-Administration, Oral,
pubmed-meshheading:12065869-Aged,
pubmed-meshheading:12065869-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12065869-Female,
pubmed-meshheading:12065869-Humans,
pubmed-meshheading:12065869-Liver Neoplasms,
pubmed-meshheading:12065869-Lung Neoplasms,
pubmed-meshheading:12065869-Lymphatic Metastasis,
pubmed-meshheading:12065869-Male,
pubmed-meshheading:12065869-Middle Aged,
pubmed-meshheading:12065869-Pancreatic Neoplasms,
pubmed-meshheading:12065869-Peritoneal Neoplasms,
pubmed-meshheading:12065869-Tegafur,
pubmed-meshheading:12065869-Treatment Outcome,
pubmed-meshheading:12065869-Uracil
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer.
|
|
pubmed:affiliation |
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan. hiueno@ncc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
